Dr. Nicholas E. Johnson, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 76
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: University of Arizona College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
UT license 8549757-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical College of Virginia Hospitals Richmond, VA
Medical groups
- Mcv Associated Physicians (1,807 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 76
- Services billed
- 156
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 40 |
| Established patient office or other outpatient visit, 10-19 minutes | 19 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Skyclarys (omaveloxolone) | 34 |
| Pregabalin Other prescribers in Salt Lake City, UT | 26 |
| Gabapentin Other prescribers in Salt Lake City, UT | 24 |
| Evrysdi (risdiplam) | 20 |
| Mexiletine Hcl | 14 |
| Baclofen Other prescribers in Salt Lake City, UT | 13 |
| Nortriptyline Hcl Other prescribers in Salt Lake City, UT | 13 |
| Modafinil Other prescribers in Salt Lake City, UT | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 23 payments worth $20,276 in total to this clinician.
| Sarepta Therapeutics, Inc. | $9,376 |
|---|---|
| Argenx US, Inc. | $4,250 |
| Novartis Pharmaceuticals Corporation | $3,300 |
| Alnylam Pharmaceuticals Inc. | $2,187 |
| Merck Sharp & Dohme LLC | $1,030 |
| Takeda Pharmaceuticals U.S.A., Inc. | $103 |
| Vertex Pharmaceuticals Incorporated | $29.50 |
| Consulting Fee | $12,002 |
|---|---|
| Education | $5,468 |
| Compensation for services other than consulting (speaking, faculty) | $2,368 |
| Food and Beverage | $236 |
| Travel and Lodging | $201 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sarepta Therapeutics, Inc. Aug 25, 2025 | Education in-kind | $5,468 |
| Sarepta Therapeutics, Inc. Mar 13, 2025 | Consulting Fee | $2,585 |
| Alnylam Pharmaceuticals Inc. Dec 18, 2025 | Consulting Fee | $2,187 |
| Argenx US, Inc. Jun 25, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $2,000 |
| Argenx US, Inc. Oct 1, 2025 | Consulting Fee VYVGART · Immunology | $1,750 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Consulting Fee | $1,030 |
| Sarepta Therapeutics, Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,018 |
| Novartis Pharmaceuticals Corporation Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,013 |
| Novartis Pharmaceuticals Corporation Oct 17, 2025 | Consulting Fee | $1,013 |
| Novartis Pharmaceuticals Corporation May 7, 2025 | Consulting Fee | $600 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Dec 18, 2025 | Consulting Fee | $2,187 |
| Novartis Pharmaceuticals Corporation Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $338 |
| Novartis Pharmaceuticals Corporation Nov 12, 2025 | Consulting Fee | $338 |
| Novartis Pharmaceuticals Corporation Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,013 |
| Novartis Pharmaceuticals Corporation Oct 17, 2025 | Consulting Fee | $1,013 |
| Argenx US, Inc. Oct 1, 2025 | Consulting Fee VYVGART · Immunology | $1,750 |
| Sarepta Therapeutics, Inc. Aug 25, 2025 | Education in-kind | $5,468 |
| Argenx US, Inc. Jul 16, 2025 | Consulting Fee | $500 |
| Argenx US, Inc. Jun 25, 2025 | Consulting Fee VYVGART HYTRULO · Neurology | $2,000 |
| Sarepta Therapeutics, Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,018 |
| Novartis Pharmaceuticals Corporation May 7, 2025 | Consulting Fee | $600 |
| Sarepta Therapeutics, Inc. Apr 24, 2025 | Travel and Lodging travel to Montreal, Canada · in-kind | $201 |
| Merck Sharp & Dohme LLC Apr 7, 2025 | Consulting Fee | $1,030 |
| Sarepta Therapeutics, Inc. Mar 13, 2025 | Consulting Fee | $2,585 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $2,273,806 in research payments for these studies, mostly to the institutions running them.
- Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1
Takeda Pharmaceuticals U.S.A., Inc. - Assessing Pediatric Endpoints in DM1 (ASPIRE-DM1)
Novartis Pharmaceuticals Corporation - END DM1 Natural History Study COnsortium, Access to data, inveustgator meetings and bionmarker tissue samples
Vertex Pharmaceuticals Incorporated - A Phase 1/2, Randomized, Double-blind, Placebo?controlled Single- and Multiple?dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VX?670 in Adult Subjects with Myotoni…
Vertex Pharmaceuticals Incorporated - Proof of concept study of GYM329 in FSHD
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.